Harmony Biosciences Holdings ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Harmony Biosciences Holdings zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Harmony Biosciences Holdings zu Deinem Portfolio hinzuzufügen.
Harmony Biosciences said on Wednesday its experimental drug for a type of rare genetic disorder failed to meet the main goal in a late-stage trial, sending its shares down 8% before the bell.
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). The RECONNECT Study did not meet the primary endpoint of improvement in social avoidance primarily due to a higher than expected placebo response rate. Kumar Budur, M...
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Cantor Global Healthcare Conference 2025 September 4, 2025 2:10 PM EDT Company Participants Jeffrey Dayno - President, CEO & Director Sandip Kapadia - Executive VP, Chief Administrative Officer & CFO Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Presentation Pete Stavropoulos Biotech Analyst Welcome ...
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30 – September 3, 2025, at the Lisbon Congress Centre in Lisbon, Portugal. Poster presentations will highlight information from the company's investigation of EPX-1...
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 4, 2025, at 2:10 p.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at...
Harmony Biosciences remains a Buy due to strong Wakix growth, profitability, and undervalued metrics despite recent setbacks. Upcoming catalysts—especially ZYN002 Phase 3 data in Fragile X—could drive significant upside, with >25% share price potential if successful, in my view. Pipeline diversification (pitolisant HD, GI, OX2R agonist, EPX-100) aims to offset Wakix patent expiry and expand lon...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.